NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and MLPRNewsWire • 07/28/22
SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive OfficerBusiness Wire • 07/12/22
NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker StudyBenzinga • 06/30/22
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker StudyPRNewsWire • 06/30/22
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker StudyPRNewsWire • 06/27/22
NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022PRNewsWire • 06/22/22
NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeCPRNewsWire • 06/01/22
NeuroSense Announces First Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 05/31/22
NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022PRNewsWire • 05/23/22
NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALSPRNewsWire • 04/11/22
NeuroSense Shares Surge Over 400% As FDA Clears Initiating Pharmacokinetic Study Of PrimeCBenzinga • 03/21/22